Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000011.xml
Dtsch Med Wochenschr 2010; 135(21): 1083-1086
DOI: 10.1055/s-0030-1253704
DOI: 10.1055/s-0030-1253704
Konsensus | Review article
Gynäkologie
© Georg Thieme Verlag KG Stuttgart · New York
Die Impfprävention HPV-assoziierter Neoplasien – eine Zusammenfassung der deutschen S3-Leitlinie
Prevention of HPV-associated neoplasias by vaccination – short version of the German S3 (level 3) guidelineFurther Information
Publication History
eingereicht: 30.9.2009
akzeptiert: 19.2.2010
Publication Date:
19 May 2010 (online)
![](https://www.thieme-connect.de/media/dmw/201021/lookinside/thumbnails/10.1055-s-0030-1253704-1.jpg)
Schlüsselwörter
Prophylaktische HPV-Impfung - S3-Leitlinie - Kurzfassung - HPV-Management Forum
Keywords
vaccination - German evidence-based medicine guideline - short-version - HPV-Management Forum
Literatur
- 1 Arbeitsgruppe HPV-Management-Forum der Paul-Ehrlich-Gesellschaft für Chemotherapie e. V. . Impfprävention HPV-assoziierter Neoplasien. S3-Leitlinie der Arbeitsgruppe HPV-Management-Forum der Paul-Ehrlich-Gesellschaft für Chemotherapie e. V. Chemother J. 2008; 17 128-171
- 2 Centers for Disease Control. http://www.cdc.gov/vaccinesafety/vaers/gardasil.htm (Stand: 06. August 2009)
- 3 Deutsche Gesellschaft für Gynäkologie und Geburtshilfe e.V .Interdisziplinäre S2k-Leitlinie für die Prävention, Diagnostik und Therapie der HPV-Infektion 2008 und präinvasiver Läsionen des weiblichen Genitale. AWMF. 015/027: 1-63
- 4 Deutsche Gesellschaft für Gynäkologie und Geburtshilfe e.V .Stellungnahme zur HPV-Impfung:. http://www.dggg.de/_download/unprotected/dggg_hpv_stm.pdf (Stand 18. August 2009)
- 5 Deutscher Bundestag .Antwort der Bundesregierung auf die Kleine Anfrage von […] Bündnis90/Die Grünen, 16/9302, 13.06.2008. http://www.bundestag.de/presse/hib/2008_06/2008_173/11.html (Stand: 06. August 2009)
- 6 European Medicines Agency .Gardasil, European Public Assessment Report, EPARs for authorised medicinal products for human use 2006, Revision 4, Published 07/09/07. http://www.emea.europa.eu/humandocs/Humans/EPAR/gardasil/gardasil.htm (Stand: 3.8.2009)
- 7 European Medicines Agency .Cervarix, European Public Assessment Report, EPARs for authorised medicinal products for human use 2007, Published 03/10/2007. http://www.emea.europa.eu/humandocs/Humans/EPAR/cervarix/cervarix.htm (Stand: 3.8.2009)
- 8 Fairley C K, Hocking J S, Gurrin L C. et al . Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect. 2009; 85 499-502
- 9 Fife K H, Wheeler C M, Koutsky L A. et al . Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women. Vaccine. 2004; 22 2943-52
- 10 FUTURE II STUDY GROUP . Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007; 356 1915-1927
- 11 Garland S M, Hernandez-Avila M, Wheeler C M. et al . Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007; 356 1928-1943
- 12 GlaxoSmithKline .Fachinformation Cervarix, September 2007. http://www.fachinfo.de/data/fi/jsearch?praep (Stand: 03.08.2009)
- 13 Harper D M, Franco E L, Wheeler C M. et al . Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004; 364 1757-1765
- 14 Harper D M, Franco E L, Wheeler C M. et al . Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: followup from a randomised control trial. Lancet. 2006; 367 1247-1255
- 15 Jahn I, Eberle A, Niehues C. et al .Gesundheitsberichterstattung des Bundes, Gebärmuttererkrankungen. Heft 37. Robert Koch-Institut; 2007
- 16 Joura E A, Leodolter S, Hernandez-Avila M. et al . Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet. 2007; 369 1693-1702
- 17 Koutsky L A, Ault K A, Wheeler C M. et al . A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002; 347 1645-1651
- 18 Mao C, Koutsky L A, Ault K A. et al . Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol. 2006; 107 18-27
- 19 Munoz N, Bosch F X, de Sanjose S. et al . Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003; 348 518-527
- 20 Paavonen J, Jenkins D, Bosch F X. et al . Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007; 369 2161-2170
- 21 Parkin D M. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006; 118 3030-3044
- 22 Parkin D M, Bray F. The burden of HPV-related cancers. Vaccine. 2006; 24 S11-S25
- 23 Perrin M, Melinand C, Darras A. Survey of European women's intention to undergo cervical smear testing.25th International Papillomavirus Conference (IPVC). Malmö, Sweden, May 8-14, 2009.
-
24
Robert Koch-Institut .
Epidemiologisches Bulletin.
2009;
32
319-338
- 25 Sanofi Pasteur MSD .Fachinformation Gardasil, August 2007. http://www.fachinfo.de/data/fi/jsearch?praep (Stand: 03.08.2009)
- 26 Slade B A at al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant. Vaccine JAMA. 2009; 302 750-757
- 27 Statistisches Bundesamt .Gesundheitswesen, Todesursachen in Deutschland 2004. Fachserie 12 / Reihe 4,. Statistisches Bundesamt; 2005
- 28 Villa L L, Costa R L, Petta C A. et al . Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebocontrolled multicentre phase II efficacy trial. Lancet Oncol. 2005; 6 271-278
- 29 Villa L L, Costa R L, Petta C A. et al . High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006; 95 1459-1466
- 30 Walboomers J M, Jacobs M V, Manos M M. et al . Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189 12-19
Prof. Dr. G. Gross
Universitätsklinik und Poliklinik für
Dermatologie und Venerologie, Universitätsklinikum
Rostock
Strempelstraße 13
18057 Rostock
Phone: 0381/4949701
Fax: 0381/4949702
Email: gerd.gross@med.uni-rostock.de